Basal cell carcinoma - Carcinoma Celloedd Gwaelodol
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
Mae briwiau briw sy'n effeithio ar groen y trwyn mewn unigolyn oedrannus yn aml yn cael eu diagnosio fel Carcinoma Celloedd Gwaelodol (Basal cell carcinoma). Mae'r trwyn yn fan cyffredin ar gyfer y math hwn o ganser y croen.
Gall Carcinoma Celloedd Gwaelodol (Basal cell carcinoma) ddangos borderi a wlserau afreolaidd.
Gellir camgymryd Carcinoma Celloedd Gwaelodol (Basal cell carcinoma) am ddafadennau.
References
Basal cell carcinoma (BCC) yw'r math mwyaf cyffredin o ganser y croen. Amlygiad golau haul yw'r prif achos. Mae bron pob achos BCC yn dangos signalau Draenogod yn orweithgar yn y dadansoddiad moleciwlaidd. Mae triniaethau gwahanol ar gael ac yn cael eu dewis yn seiliedig ar y risg y bydd yn digwydd eto, pwysigrwydd cadw meinwe, dewis y claf, a maint y clefyd.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas yw'r math mwyaf cyffredin o ganser y croen ymhlith oedolion â chroen gweddol 50 oed a hŷn. Mae eu niferoedd yn cynyddu ledled y byd, yn bennaf oherwydd bod yn agored i olau'r haul. Gall rhai cyflyrau genetig wneud pobl yn dueddol o ddatblygu'r canserau hyn yn iau. Basal cell carcinomas yn amrywio o ran difrifoldeb, yn amrywio o friwiau arwynebol neu nodwlaidd hawdd eu trin i rai mwy helaeth y mae angen eu trafod mewn timau meddygol arbenigol. Mae'r prognosis yn dibynnu ar y tebygolrwydd y bydd canser yn dychwelyd neu ei allu i niweidio meinwe cyfagos. Llawfeddygaeth yw'r driniaeth safonol ar gyfer y rhan fwyaf o achosion, gan sicrhau tynnu manwl gywir a siawns isel y bydd yn digwydd eto. Gall dulliau llai ymledol drin briwiau arwynebol yn effeithiol.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Y driniaeth sylfaenol ar gyfer BCC yw llawdriniaeth. Ar gyfer BCC risg uchel neu gylchol, yn enwedig mewn meysydd critigol, argymhellir llawdriniaeth a reolir yn ficrograffig. Gallai cleifion â BCC arwynebol risg isel ystyried triniaethau amserol neu ddulliau dinistriol. Mae therapi ffotodynamig yn gweithio'n dda ar gyfer BCCs nodwlaidd arwynebol a risg isel. Ar gyfer BCC datblygedig lleol neu fetastatig, argymhellir atalyddion draenogod (vismodegib, sonidegib) . Os bydd clefyd yn datblygu neu'n anoddefiad i atalyddion Draenogod, gellir ystyried imiwnotherapi â anti-PD1 antibody (cemiplimab) . Mae radiotherapi yn opsiwn da i gleifion na allant gael llawdriniaeth, yn enwedig cleifion hŷn. Gellid ystyried electrocemotherapi os nad yw llawdriniaeth neu radiotherapi yn opsiwn.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Mae ffactorau risg yn cynnwys dod i gysylltiad â golau uwchfioled, therapi ymbelydredd, amlygiad hirdymor i arsenig a swyddogaeth system imiwnedd wael (e.e. trawsblannu organau). Mae dod i gysylltiad â golau UV yn ystod plentyndod yn arbennig o niweidiol.
Ar ôl gwneud diagnosis trwy fiopsi, mae triniaeth fel arfer trwy dynnu llawfeddygol. Gall hyn fod trwy doriad syml os yw'r canser yn fach; Os nad yw'r canser yn fach, argymhellir llawdriniaeth Mohs yn gyffredinol.
Mae carsinoma celloedd gwaelodol yn cyfrif am o leiaf 32% o'r holl ganserau yn fyd-eang. O blith canserau'r croen heblaw melanoma, mae tua 80% yn ganserau celloedd gwaelodol. Yn yr Unol Daleithiau, mae tua 35% o wrywod gwyn a 25% o ferched gwyn yn cael eu heffeithio gan garsinoma celloedd gwaelodol ar ryw adeg yn eu bywydau.
○ Diagnosis a Thriniaeth
#Dermoscopy
#Skin biopsy
#Mohs surgery